9 research outputs found
Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance
Objective: To determine matrix metalloproteinase-2 and survivin expressions in endometrial cancers, their relation to clinical and histologic parameters and to investigate any difference in the expression of these markers between endometrioid and non-endometrioid cancers
SERVİKAL KARSİNOMLARDA ANJİOGENEZ, PROLİFERATİF AKTİVİTE VE EPİDERMAL GROWTH FAKTÖR RESEPTÖR EKSPRESYONU
Servikal karsinomlu hastalarda evre ve tümör derecesi dışında başka prognostik faktörler de önemli rol oynamaktadır
ENDOMETRİOİD ADENOKARSİNOMLARDA HEAT - SHOCK PROTEİN 70, 90 VE TENASİN EKSPRESYONUNUN MYOMETRİAL İNVAZYON DERİNLİĞİ İLE İLİŞKİSİ
Endometrial kanserli olgularda HSP 70, 90 ve tanısının immunohisto kimyasal ekspresyonunu inceleme
Rektum kanseri tanısıyla radyoterapi uygulanmış geriatrik hastaların tedavi sonuçları ve tolerabilitesinin G-8 geriatri skoru eşliğinde değerlendirilmesi: TROD13-003 Ulusal çok merkezli çalışması
Adjuvant systemic therapies in women with operable breast cancer A daily medical practice in a single institution
SERVİKAL KANSERLERDE KATEPSİN D1, SİKLİN D1 VE NM23 EKSPRESYONUNUN İMMUNOHİSTOKİMYASAL YÖNTEMLE İNCELENMESİ
Siklinler, hücre siklus progresyonunun regülasyonunda yer alırlar
Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer
Aim The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer. Method This was a randomized trial which included a total of 330 patients from two institutions. Patients with locally advanced (T3-4N0M0, TxN+M0) rectal cancer were randomized into 8- and 12-week interval groups. All the patients received long-course CRT (45 Gy in 1.8 Gy fractions and concomitant oral capecitabine or 5-fluorouracil infusion). Surgery was performed at either 8 or 12 weeks after CRT. The primary end-point was pCR. Secondary end-points were sphincter preservation, postoperative morbidity and mortality. Results Two-hundred and fifty-two patients (n = 125 in the 8-week group, n = 127 in the 12-week group) were included. Demographic and clinical characteristics were similar between groups. The overall pCR rate was 17.9% (n = 45): 12% (n = 15) in the 8-week group and 23.6% (n = 30) in the 12-week group (P = 0.021). Sphincter-preserving surgery was performed in 107 (85.6%) patients which was significantly higher than the 94 (74%) patients in the 12-week group (P = 0.016). Postoperative mortality was seen in three (1.2%) patients overall and was not different between groups (1.6% in 8 weeks vs 0.8% in 12 weeks, P = 0.494). Groups were similar in anastomotic leak (10.8% in 8 weeks vs 4.5% in 12 weeks, P = 0.088) and morbidity (30.4% in 8 weeks and 20.1% in 12 weeks, P = 0.083). Conclusion Extending the interval between CRT and surgery from 8 to 12 weeks resulted in a 2-fold increase in pCR rate without any difference in mortality and morbidity